---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-005127"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2024-02-22T23:59:59+00:00"
generated_at: "2026-06-05T19:32:20.691099+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Monopar announces promising preclinical data for MNPR-101 radiopharma; Phase 1 trial in Australia cleared

## Summary
- MNPR-101 targets uPAR, expressed in majority of triple-negative breast, colorectal, and pancreatic cancers.
- Optimized MNPR-101-Zr imaging agent shows increased tumor uptake and reduced healthy tissue uptake in PET studies.
- Single injection of MNPR-101 conjugated to Ac-225 or other therapeutic isotope led to near complete tumor elimination in mouse models.
- Received HREC clearance in Australia to start Phase 1 dosimetry trial of MNPR-101-Zr in advanced cancer patients.
- Company plans to present results at an upcoming scientific meeting.

## SEC filing metadata
- accession: 0001437749-24-005127
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2024-02-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774924005127/0001437749-24-005127-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774924005127/mnpr20240221_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-005127
- JSON: https://secwatch.observer/filing/0001437749-24-005127.json
- Plain text: https://secwatch.observer/filing/0001437749-24-005127.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.